Published in J Immunol on February 01, 2009
Immune cell promotion of metastasis. Nat Rev Immunol (2015) 2.15
Regulatory T cells in nonlymphoid tissues. Nat Immunol (2013) 1.69
CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am J Pathol (2010) 1.69
Targeting regulatory T cells in cancer. Cancer Res (2011) 1.66
CCR5 dictates the equilibrium of proinflammatory IL-17+ and regulatory Foxp3+ T cells in fungal infection. J Immunol (2010) 1.62
TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. J Exp Med (2015) 1.59
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 1.55
A distinct chemokine axis does not account for enrichment of Foxp3(+) CD4(+) T cells in carcinogen-induced fibrosarcomas. Immunology (2015) 1.40
Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev (2014) 1.38
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood (2009) 1.28
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity. Cell (2015) 1.26
Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther (2011) 1.26
Natural and induced T regulatory cells in cancer. Front Immunol (2013) 1.15
Regulatory T cell migration during an immune response. Trends Immunol (2012) 1.10
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res (2014) 1.08
The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm (2011) 1.08
Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol (2013) 1.06
The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol (2012) 1.05
Basic principles of tumor-associated regulatory T cell biology. Trends Immunol (2012) 1.05
Specific recruitment of γδ regulatory T cells in human breast cancer. Cancer Res (2013) 1.01
Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol (2014) 1.00
CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One (2011) 1.00
Stromal reengineering to treat pancreas cancer. Carcinogenesis (2014) 1.00
Home sweet home: the tumor microenvironment as a haven for regulatory T cells. Front Immunol (2013) 0.99
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res (2011) 0.99
TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest (2015) 0.96
Roles of regulatory T cells in cancer immunity. Int Immunol (2016) 0.95
STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon. Neoplasia (2013) 0.93
The role of regulatory T cells in cancer. Immune Netw (2009) 0.93
Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. Proc Natl Acad Sci U S A (2014) 0.92
Pancreatic cancer, inflammation, and microbiome. Cancer J (2014) 0.91
Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med (2012) 0.91
Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J (2013) 0.90
Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother (2010) 0.90
Regulatory T cells in human ovarian cancer. J Oncol (2012) 0.90
Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol (2010) 0.90
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal (2012) 0.88
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research. Cancer Immun (2009) 0.88
RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia (2015) 0.87
CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis. Arthritis Rheum (2009) 0.87
The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br J Cancer (2014) 0.86
An aberrant thymus in CCR5-/- mice is coupled with an enhanced adaptive immune response in fungal infection. J Immunol (2011) 0.86
Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and upregulation of IL-1Ra in melanoma model. PLoS One (2012) 0.86
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84
Graft-derived CCL2 increases graft injury during antibody-mediated rejection of cardiac allografts. Am J Transplant (2014) 0.83
Homing of regulatory T cells to human skin is important for the prevention of alloimmune-mediated pathology in an in vivo cellular therapy model. PLoS One (2012) 0.83
Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer. Cancer Sci (2014) 0.82
Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol (2015) 0.82
Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma. Exp Ther Med (2012) 0.82
Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. Int J Colorectal Dis (2010) 0.81
Optimal population of FoxP3+ T cells in tumors requires an antigen priming-dependent trafficking receptor switch. PLoS One (2012) 0.80
CC chemokine receptor 5: the interface of host immunity and cancer. Dis Markers (2014) 0.79
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. Front Oncol (2015) 0.79
The fatal alliance of cancer and T cells: How pancreatic tumor cells gather immunosuppressive T cells. Oncoimmunology (2014) 0.79
Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. Medicine (Baltimore) (2016) 0.78
Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs. Oncoimmunology (2016) 0.78
Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. J Cancer Res Clin Oncol (2011) 0.77
The role of chemoattractant receptors in shaping the tumor microenvironment. Biomed Res Int (2014) 0.77
Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion. Oncoimmunology (2015) 0.76
Immunotherapy with methyl gallate, an inhibitor of Treg cell migration, enhances the anti-cancer effect of cisplatin therapy. Korean J Physiol Pharmacol (2016) 0.75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol (2017) 0.75
T-cell programming in pancreatic adenocarcinoma: a review. Cancer Gene Ther (2016) 0.75
Regulatory T cells in colorectal cancer: from biology to prognostic relevance. Cancers (Basel) (2011) 0.75
Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol (2015) 0.75
Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol (2016) 0.75
Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer. Trends Mol Med (2017) 0.75
Cancer-FOXP3 directly activated CCL5 to recruit FOXP3(+)Treg cells in pancreatic ductal adenocarcinoma. Oncogene (2016) 0.75
Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression. Cell Death Dis (2017) 0.75
Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model. Mol Ther Oncolytics (2017) 0.75
Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. Cell Rep (2017) 0.75
Immune Cell Population in Ovarian Tumor Microenvironment. J Cancer (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Regulatory T cells and immune tolerance. Cell (2008) 18.77
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
Regulatory T cells in autoimmmunity*. Annu Rev Immunol (2000) 9.36
Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A (2004) 9.33
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol (2002) 9.18
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Regulatory T cells in the control of immune pathology. Nat Immunol (2001) 6.98
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Natural regulatory T cells in infectious disease. Nat Immunol (2005) 6.49
Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med (2001) 5.56
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med (1982) 5.47
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A (1999) 4.46
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res (2006) 3.38
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology (2007) 3.34
CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood (2004) 2.80
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res (1984) 2.74
Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood (2008) 2.72
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (2007) 2.68
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med (2005) 2.51
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett (2007) 2.43
Regulatory T cells and cancer. Curr Opin Immunol (2007) 2.41
The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol (2006) 2.06
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther (2008) 1.90
Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood (2005) 1.89
CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med (2006) 1.88
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res (2008) 1.85
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer (2008) 1.79
A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res (2003) 1.78
Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate (2006) 1.76
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer (2007) 1.64
Homing to suppress: address codes for Treg migration. Trends Immunol (2005) 1.56
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol (2006) 1.53
Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett (1997) 1.41
CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol (2007) 1.35
Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer (2005) 1.34
Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res (1989) 1.31
Distinctive role of CCR7 in migration and functional activity of naive- and effector/memory-like Treg subsets. Eur J Immunol (2007) 1.30
Alloantigen-enhanced accumulation of CCR5+ 'effector' regulatory T cells in the gravid uterus. Proc Natl Acad Sci U S A (2006) 1.27
CD25+ CD4+ regulatory T-cells in cancer. Immunol Res (2005) 1.26
Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother (2006) 1.26
The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol (2003) 1.17
A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol (2002) 1.17
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis (2006) 1.16
Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol (2006) 1.15
Systemic and local characterization of regulatory T cells in a chronic fungal infection in humans. J Immunol (2006) 1.15
Viral chemokine-binding proteins. J Leukoc Biol (2002) 1.13
Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol (2007) 1.13
Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics. J Biol Chem (2001) 1.11
Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model. Gene Ther (2007) 1.09
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch (2004) 1.05
Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem (2000) 1.00
Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol (2007) 0.95
Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4+CD25+ regulatory T cells in MRL/lpr mice. Arthritis Res Ther (2007) 0.90
Host absence of CCR5 potentiates dendritic cell vaccination. J Immunol (2003) 0.89
Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol (2008) 0.86
Membrane-bound CC chemokine inhibitor 35K provides localized inhibition of CC chemokine activity in vitro and in vivo. J Immunol (2006) 0.85
A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res (2002) 0.83
Genome-wide expression profiling during protection from colitis by regulatory T cells. Inflamm Bowel Dis (2008) 0.82
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Peripheral education of the immune system by colonic commensal microbiota. Nature (2011) 5.80
Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol (2009) 4.53
The accordion severity grading system of surgical complications. Ann Surg (2009) 4.45
A two-step process for thymic regulatory T cell development. Immunity (2008) 4.29
Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity (2008) 3.56
Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat Immunol (2009) 3.38
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg (2005) 3.04
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res (2004) 2.78
Antigen-specific peripheral shaping of the natural regulatory T cell population. J Exp Med (2008) 2.68
Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg (2004) 2.65
Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol (2007) 2.50
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
A broad range of self-reactivity drives thymic regulatory T cell selection to limit responses to self. Immunity (2012) 2.10
Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg (2012) 1.91
Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol (2005) 1.76
Cancer causes increased mortality and is associated with altered apoptosis in murine sepsis. Crit Care Med (2010) 1.68
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res (2013) 1.67
Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol (2007) 1.66
Therapeutic management of intracystic papillary carcinoma of the breast: the roles of radiation and endocrine therapy. Am J Surg (2007) 1.65
Pattern of venous collateral development after splenic vein occlusion in an extended Whipple procedure : comparison with collateral vein pattern in cases of sinistral portal hypertension. J Gastrointest Surg (2011) 1.60
Mesh reinforcement of pancreatic transection decreases incidence of pancreatic occlusion failure for left pancreatectomy: a single-blinded, randomized controlled trial. Ann Surg (2012) 1.58
Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause (2010) 1.56
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 1.55
Positive margin rates following breast-conserving surgery for stage I-III breast cancer: palpable versus nonpalpable tumors. J Surg Res (2012) 1.53
A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing. Mol Cancer Ther (2010) 1.53
Predictors of primary breast abscesses and recurrence. World J Surg (2009) 1.51
A tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol (2005) 1.47
Isolation of right main and right sectional portal pedicles for liver resection without hepatotomy or inflow occlusion. J Am Coll Surg (2007) 1.46
Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer (2007) 1.46
Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res (2007) 1.45
Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother (2007) 1.45
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res (2006) 1.39
Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J Immunol (2002) 1.37
Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol (2010) 1.35
Laparoscopic gastric resection for gastrointestinal stromal tumors. Surg Endosc (2008) 1.34
Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure. J Am Coll Surg (2012) 1.33
Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol (2003) 1.32
Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res (2009) 1.30
The role of poverty rate and racial distribution in the geographic clustering of breast cancer survival among older women: a geographic and multilevel analysis. Am J Epidemiol (2008) 1.28
Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg (2007) 1.28
CD25+ CD4+ regulatory T-cells in cancer. Immunol Res (2005) 1.26
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov (2014) 1.26
Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother (2006) 1.26
Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother (2009) 1.23
Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg (2002) 1.22
Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother (2005) 1.22
An innovative microarray strategy identities informative molecular markers for the detection of micrometastatic breast cancer. Clin Cancer Res (2005) 1.21
Photoacoustic microscopy of tyrosinase reporter gene in vivo. J Biomed Opt (2011) 1.21
Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn (2003) 1.20
CD28 facilitates the generation of Foxp3(-) cytokine responsive regulatory T cell precursors. J Immunol (2010) 1.19
Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol (2010) 1.18
Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg (2007) 1.18
Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg (2009) 1.16
Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol (2006) 1.15
Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem (2004) 1.15
Rare development of Foxp3+ thymocytes in the CD4+CD8+ subset. J Immunol (2009) 1.14
Becoming self-aware: the thymic education of regulatory T cells. Curr Opin Immunol (2010) 1.12
Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer (2007) 1.12
Geographic clustering of adequate diagnostic follow-up after abnormal screening results for breast cancer among low-income women in Missouri. Ann Epidemiol (2007) 1.10
Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res (2009) 1.08
Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford) (2013) 1.08
Treatment and outcomes of patients with primary breast sarcoma. Am J Surg (2008) 1.07
Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat (2007) 1.07
Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer (2002) 1.07
"Sideways": results of repair of biliary injuries using a policy of side-to-side hepatico-jejunostomy. Ann Surg (2009) 1.07
Proposal for definition and severity grading of pancreatic anastomosis failure and pancreatic occlusion failure. Surgery (2007) 1.07
T cell tolerance and immunity to commensal bacteria. Curr Opin Immunol (2012) 1.06
Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery (2012) 1.06
Bile duct injuries in the era of laparoscopic cholecystectomies. Surg Clin North Am (2010) 1.05
Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg (2014) 1.03